These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21734353)

  • 21. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
    Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
    Hayashi K; Katano Y; Kuzuya T; Tachi Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Med Virol; 2012 Mar; 84(3):438-44. PubMed ID: 22246829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2009 Mar; 81(3):452-8. PubMed ID: 19152407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Miyakawa Y; Kumada H
    Intervirology; 2007; 50(5):361-8. PubMed ID: 17728547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Matsuda M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    Intervirology; 2005; 48(6):372-80. PubMed ID: 16024941
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
    Toyoda H; Kumada T; Hayashi K; Honda T; Katano Y; Goto H; Kawaguchi T; Murakami Y; Matsuda F
    J Med Virol; 2011 Sep; 83(9):1559-64. PubMed ID: 21739446
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
    Miyasaka A; Kumagai I; Abe K; Suzuki K
    Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients.
    El-Shamy A; Shoji I; El-Akel W; Bilasy SE; Deng L; El-Raziky M; Jiang DP; Esmat G; Hotta H
    J Clin Microbiol; 2012 Dec; 50(12):3886-92. PubMed ID: 22993188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
    Yano Y; Seo Y; Miki A; Saito M; Kato H; Hamano K; Oya M; Ouchi S; Fujisawa T; Yamada H; Yamashita Y; Tani S; Hirohata S; Yoon S; Kitajima N; Kitagaki K; Kawara A; Nakashima T; Yu H; Maeda T; Azuma T; El-Shamy A; Hotta H; Hayashi Y;
    Int J Mol Med; 2012 Nov; 30(5):1048-52. PubMed ID: 22899224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2010 Apr; 82(4):575-82. PubMed ID: 20166188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
    Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
    J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation.
    Fukuhara T; Taketomi A; Okano S; Ikegami T; Soejima Y; Shirabe K; Maehara Y
    J Hepatol; 2010 May; 52(5):672-80. PubMed ID: 20346532
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.
    Kondo C; Atsukawa M; Tsubota A; Itokawa N; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Sakamoto C
    J Viral Hepat; 2012 Sep; 19(9):615-22. PubMed ID: 22863265
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    Intervirology; 2009; 52(6):301-9. PubMed ID: 19729953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy.
    Nakamoto S; Imazeki F; Arai M; Yasui S; Nakamura M; Haga Y; Sasaki R; Kanda T; Shirasawa H; Yokosuka O
    Int J Mol Sci; 2015 Sep; 16(9):21177-90. PubMed ID: 26370958
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Amino acid substitution in the core protein has no impact on relapse in hepatitis C genotype 1 patients treated with peginterferon and ribavirin.
    Inoue Y; Hiramatsu N; Oze T; Yakushijin T; Mochizuki K; Fukuda K; Mita E; Haruna Y; Inoue A; Imai Y; Hosui A; Miyagi T; Yoshida Y; Tatsumi T; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N
    J Med Virol; 2011 Mar; 83(3):419-27. PubMed ID: 21264862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Substitutions in interferon sensitivity-determining region and hepatocarcinogenesis after hepatitis C virus eradication.
    Yasuda S; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Hayashi K; Toyoda H; Kumada T; Hirooka Y; Goto H
    J Gastroenterol Hepatol; 2018 Nov; 33(11):1904-1911. PubMed ID: 29744922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors.
    Kurosaki M; Tanaka Y; Nishida N; Sakamoto N; Enomoto N; Honda M; Sugiyama M; Matsuura K; Sugauchi F; Asahina Y; Nakagawa M; Watanabe M; Sakamoto M; Maekawa S; Sakai A; Kaneko S; Ito K; Masaki N; Tokunaga K; Izumi N; Mizokami M
    J Hepatol; 2011 Mar; 54(3):439-48. PubMed ID: 21129805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.